Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 17/20 | 0.54 |
| ▸ | CCND1 | P24385 | 17/20 | 0.54 |
| ▸ | CCNE2 | O96020 | 12/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 12/20 | 0.44 |
| ▸ | CDK2 | P24941 | 12/20 | 0.44 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.42 |
| ▸ | CDK1 | P06493 | 2/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.42 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7964689 | 0.72 | CDK4 (0.56) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL5827076 | 0.69 | CDK4 (0.46) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL5826536 | 0.68 | CDK4 (0.46) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL7937098 | 0.67 | CRHR1 (0.46) | CDK4CCND1HPGDKDM4EHSD17B10 | |
| SCHEMBL7967892 | 0.67 | CDK4 (0.50) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL7965911 | 0.65 | CRHR1 (0.63) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL7965323 | 0.64 | CDK4 (0.61) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL11441262 | 0.63 | L3MBTL1 (0.47) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL5826687 | 0.63 | KDR (0.54) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL8113413 | 0.63 | CDK4 (0.58) | CDK4CCND1CCNE2CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6995163-B2 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | EISAI CO., LTD. (JP) | 2006-02-07 | — | — | US | disclosed |
| US-6951865-B2 | Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same | EISAI CO., LTD. (JP) | 2005-10-04 | — | — | US | disclosed |
| US-6927221-B2 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | EISAI CO., LTD. (JP) | 2005-08-09 | — | — | US | disclosed |
| EP-1408040-B1 | Tricyclic fused heterocyclic compounds as CRFantagonists | EISAI CO LTD (JP) | 2005-07-27 | — | — | EP | disclosed |
| EP-1238979-B1 | FUSED HETEROTRICYCLIC COMPOUNDS, PROCESS FOR PREPARING THE COMPOUNDS AND DRUGS CONTAINING THE SAME | EISAI CO LTD (JP) | 2005-03-02 | — | — | EP | disclosed |
| US-20050004147-A1 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | EISAI CO., LTD. | 2005-01-06 | — | — | US | disclosed |
| US-20050004159-A1 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | EISAI CO., LTD. | 2005-01-06 | — | — | US | disclosed |
| EP-1408040-A1 | Tricyclic fused heterocyclic compounds as CRFantagonists | Eisai Co., Ltd. (JP) | 2004-04-14 | — | — | EP | disclosed |
| US-20030078277-A1 | Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1238979-A1 | FUSED HETEROTRICYCLIC COMPOUNDS, PROCESS FOR PREPARING THE COMPOUNDS AND DRUGS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078277-A1 | Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same | NR3C2, CRHR1, CRHR2 | CDK4 800/4885CCND1 1358/4885CCNE2 1060/4885 |
| US-20050004159-A1 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | CRHR2, CRHR1, NR3C2 | CDK4 744/4885CCND1 792/4885CCNE2 549/4885 |
| US-20050004147-A1 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | CRHR2, CRHR1, NR3C2 | CDK4 744/4885CCND1 792/4885CCNE2 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.